CEO of Moderna Therapeutics
Appears in 2 stories
CEO, Moderna - Leading Moderna's oncology pipeline
Metastatic breast cancer typically kills most patients within five years. A small group of women vaccinated in a Duke University clinical trial two decades ago have defied that prognosis entirely—all remain alive today. Researchers discovered these survivors still carry specialized immune cells capable of recognizing their cancer, pointing to a mechanism that could make therapeutic cancer vaccines work reliably.
Updated Jan 31
CEO, Moderna - Positioning Moderna's cancer vaccine pipeline as core to post-pandemic strategy
Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit—until now. On January 20, 2026, Moderna and Merck reported that their personalized mRNA vaccine, combined with the immunotherapy Keytruda, cut the risk of melanoma recurrence or death by 49% at five years in a Phase 2b trial of 157 patients. The sustained result—identical to the three-year mark—suggests the vaccine permanently reprograms immune surveillance rather than offering temporary protection.
Updated Jan 25
No stories match your search
Try a different keyword
The week's most important stories, delivered every Monday. No spam, unsubscribe anytime.
How would you like to describe your experience with the app today?
